Advanced search
Publication Cover
Harvard Review of Psychiatry Volume 11, 2003 - Issue 2
Journal homepage
54
Views
1
CrossRef citations to date
0
Altmetric
Research Article

31P-Magnetic Resonance Spectroscopy and Thyroid Hormones in Major Depressive Disorder: Toward a Bioenergetic Mechanism in Depression?

Dan V. Iosifescu From the Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital
&
Perry F. Renshaw The Brain Imaging Center, McLean Hospital, Harvard Medical School
Pages 51-63 | Published online: 03 Jul 2009

  • Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologie catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94.
  • Simon GE, VonKorff M, Ustun TB, Gater R, Gureje O, Sartorius N. Is the lifetime risk of depression actually increasing? J Clin Epidemiol 1995;48:1109-18.
  • Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001;49(8):1-114.
  • Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
  • Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
  • Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
  • Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 2001;62(suppl 4):7-11.
  • Nierenberg AA. Long-term management of chronic depression. J CUn Psychiatry 2001;62(suppl 6):17-21.
  • Mayberg HS, Lewis PJ, Regenold W, Wagner HN Jr. Paralimbic hypoperfusion in unipolar depression. J Nucl Med 1994;35:929-34.
  • Austin MP, Dougall N, Ross M, Murray C, O'Carroll RE, Moffoot A, et al. Single photon emission tomography with 99mTc-exametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum. J Affect Disord 1992;26:31-43.
  • Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158:899-906.
  • Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001;58:631-40.
  • Navarro V, Gasto C, Lomena F, Mateos JJ, Marcos T, Portella MJ. Normalization of frontal cerebral perfusion in remitted elderly major depression: a 12-month follow-up SPECT study. Neuroimage 2002;16:781-7.
  • Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, VaMIi K, et al. Increased orbitofrontal cortex levels of cytosolic choline in depressed adolescents. Biol Psychiatry 2000;48:1053-61.
  • Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 1999;156:1638-40.
  • Ke Y, Cohen BM, Lowen S, Hiroshima F, Nassar L, Renshaw PF. Biexponential transverse relaxation (T(2)) of the proton MRS creatine resonance in human brain. Magn Reson Med 2002;47:232-8.
  • Renshaw PF, Parow AM, Hirashima F, Ke Y, Moore CM, Frederick Bde B, et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001;158:2048-55.
  • Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 1994;241:354-71.
  • Morikawa S, Inubushi T, Kitoh K, Kido C, Nozaki M. Chemical assessment of phospholipid and phosphoenergetic metabolites in regenerating rat liver measured by in vivo and in vitro 31PNMR. Biochim Biophys Acta 1992;1117:251-7.
  • Renshaw PF, Summers JJ, Renshaw CE, Hines KG, Leigh JS Jr. Changes in the 3IP-NMR spectra of cats receiving lithium chloride systemically. Biol Psychiatry 1986;21:694-8.
  • Yildiz A, Demopulos CM, Moore CM, Renshaw PF, Sachs GS. Effect of lithium on phosphoinositide metabolism in human brain: a proton decoupled 31-P magnetic resonance spectroscopy study. Biol Psychiatry 2001;50:3-7.
  • Kato T, Shioiri T, Murashita J, Inubushi T. Phosphorus-31 magnetic resonance spectroscopic observations in 4 cases with anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:719-24.
  • Kato T, Murashita J, Shioiri T, Hamakawa H, Inubushi T. Effect of photic stimulation on energy metabolism in the human brain measured by 31P-MR spectroscopy. J Neuropsychiatry Clin Neurosci 1996;8:417-22.
  • Pissarek M, Garcia de Arriba S, Schafer M, Sieler D, Nieber K, Dies P. Changes by short-term hypoxia in the membrane properties of pyramidal cells and the levels of purine and pyrimidine nucleotides in slices of rat neocortex: effects of agonists and antagonists of ATP-dependent potassium channels. Naunyn Schmiederbergs Arch Pharmacol 1998;368:430-9.
  • Younkin D. Magnetic resonance spectroscopy in hypoxiaischemia encephabpathy. Clin Invest Med 1993;16:115-21.
  • Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992;26:223-30.
  • Pettegrew JW, Levine J, Gershon S, Stanley JA, ServanSchreiber D, Panchalingam K, et al. 31P-MRS study of acetylL-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4:61-6.
  • Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997;154:116-8.
  • VoIz HP, Rzanny R, Riehemann S, May S, Hegewald H, Preussler B, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry ClinNeurosci 1998;248:289-95.
  • Purdon AD, Rapoport SI. Energy requirements for two aspects of phospholipid metabolism in mammalian brain. Biochem J 1998;335:313-8.
  • Felber SR, Pycha R, Hummer M, Aichner FT, Fleischhacker WW. Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy. Biol Psychiatry 1993;33:651-4.
  • Argov Z, Renshaw PF, Boden B, Winokur A, Bank WJ. Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats. J Clin Invest 1988;81:1695-701.
  • Moka D, Theissen P, Linden A, Waters W, Schicha H. The effect of hyper- and hypothyroidism on the energy metabolism of skeletal muscles-a study using 31P-magnetic resonance spectroscopy. Nuklearmedizin 1991;30:77-83.
  • Hagspiel KD, von Weymarn C, McKinnon G, Haldemann R, Marincek B, von Schulthess GK. Effect of hypothyroidism on phosphorus metabolism in muscle and liver: in vivo P-31 MR spectroscopy study. J Magn Reson Imaging 1992;2: 527-32.
  • Kaminsky P, Robin-Lherbier B, Brunette F, Escanye JM, Walker P, Klein M, et al. Energetic metabolism in hypothyroid skeletal muscle, as studied by phosphorus magnetic resonance spectroscopy. J Clin Endocrinol Metab 1992;74:124-9.
  • Taylor DJ, Rajagopalan B, Radda GK. Cellular energetics in hypothyroid muscle. Eur J Clin Invest 1992;22:358-65.
  • Wiles CM, Young A, Jones DA, Edwards RH. Muscle relaxation rate, fiber-type composition and energy turnover in hyper- and hypo-thyroid patients. Clin Sci (Lond) 1979;57:375-84.
  • Kaminsky P, Klein M, Robin-Lherbier B, Walker P, Escanye JM, Brunotte F, et al. 31P-NMR study of different hypothyroid states in rat leg muscle. Am J Physiol 1991;261:E706-12.
  • Okamoto R, Leibfritz D. Adverse effects of reverse triiodothyronine on cellular metabolism as assessed by 1H and 3 IP NMR spectroscopy. Res Exp Med (Berl) 1997;197:211-7.
  • Smith CD, Ain KB. Brain metabolism in hypothyroidism studied with 3 IP magnetic-resonance spectroscopy. Lancet 1996;346:619-20.
  • Seymour AM, Eldar H, Radda GK. Hyperthyroidism results in increased glycolytic capacity in the rat heart. A 31P-NMR study. Biochim Biophys Acta 1990;1066:107-16.
  • Kaminsky P, Robin-Lherbier B, Walker P, Brunotte F, Escanye JM, Klein M, et al. Muscle bioenergetic impairment in hyperthyroid man: a study by 31P NMR spectroscopy. Acta Endocrinol (Copenh) 1991;124:271-7.
  • Theissen P, Kaldewey S, Moka D, Bunke J, Voth E, Schicha H. 31P-magnetic resonance spectroscopy: impaired energy metabolism in latent hyperthyroidism. Nuklearmedizin 1993;32:134-9.
  • Erkintalo M, Bendahan D, Mattel JP, Fabreguettes C, Vague P, Cozzone PJ. Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism 1998;47:769-76.
  • Feldmesser-Reiss EE. The application of triiodothyronine in the treatment of mental disorders. J Nervous Mental Dis 1958;127:540-6.
  • Flach FF, Celian CI, Rawson RW. Treatment of psychiatric disorders with triiodothyronine. Am J Psychiatry 1958;114: 841-2.
  • Wilson IC, Prange AJ Jr, Lara PP. L-Triiodothyronine alone and with imipramine in the treatment of depressed women. In: Prange AJ Jr, ed. The thyroid axis, drugs, and behavior. New York: Raven Press, 1974:49-62.
  • Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry 1970;126:1667-9.
  • Ogura C, Okuma T, Uchida Y, Imai S, Yogi H. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974;28:179-86.
  • Banki C. The use of triiodothyronine in the treatment of depression. Orv Hetil 1975;116:2543-6.
  • Banki CM. Cerebrospinal fluid amine metabolites after combined amitryptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977;11:311-5.
  • Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3, and antidepressants in depression. J Int Med Res 1979;7:138-46.
  • Schwarcz G, Halaris A, Baxter L, Escobar J, Thompson M, Young M. Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiodothyronine. Am J Psychiatry 1984;141:1614-6.
  • Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramineresistant recurrent depression, I: an open clinical trial of adjunctive 1-triiodothyronine. J Clin Psychiatry 1989;50:385-8.
  • Birkenhager TK, Vegt M, Nolen WA. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. Pharmacopsychiatry 1997;30:23-6.
  • Steiner M, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Failure of 1-triiodothyronine to potentiate tricyclic antidepressant response. Curr Ther Res 1978;23:655-9.
  • Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by 1-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982 ;139: 34-8.
  • Gitlin MJ, Weiner H, Fairbanks L, Hershman JM, Friedfeld N. Failure of T3 to potentiate tricyclic antidepressant response. J Affective Disord 1987;13:267-72.
  • Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-51.
  • Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebocontrolled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
  • Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation--a pilot study. J Affect Disord 1998;49:235-9.
  • Aronson R, Offinan HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996;53:842-8.
  • Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998;18:444-55.
  • Rudas S, Schmitz M, Hehler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. Biol Psychiatry 1999;45:229-33.
  • Joffe RT. Triiodothyronine potentiation of the antidepressant effect of phenelzine. J Clin Psychiatry 1988;49:409-10.
  • Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969;126:457-69.
  • Wilson IC, Prange AJ Jr, McClane TK, Rabon AM, Lipton M. Thyroid-hormone enhancement of imipramine in nonretarded depressions. N Engl J Med 1970;282:1063-7.
  • Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972;26:229-33.
  • Coppen A, Whybrow P, Noguera R, Maggs R, Prange AJ Jr. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26:234-41.
  • Feighner JP, King LJ, Schuckit MA, Croughan J, Briscoe W. Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972;128:1230-8.
  • Steiner M, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Failure of L-triiodothyronine (T3) to potentiate tricyclic antidepressants. Curr Ther Res Clin Exp 1978;23:655-9.
  • Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-22.
  • Dratman MB, Crutchfield FL, Schoenhoff MB. Transport of iodothyronines from bloodstream to brain: contributions by blood:brain and choroid plexus:cerebrospinal fluid barriers. Brain Res 1991;554:229-36.
  • Rozanov CB, Dratman MB. Immunohistochemical mapping of brain triiodothyronine reveals prominent localization in central noradrenergic systems. Neuroscience 1996;74:897-915.
  • Cheng LY, Outterbridge LV, Covatta ND, Martens DA, Gordon JT, Dratman MB. Film autoradiography identifies unique features of [125I]3,3'5'-(reverse) triiodothyronine transport from blood to brain. J Neurophysiol 1994;72:380-91.
  • Gordon JT, Kaminski DM, Rozanov CB, Dratman MB. Evidence that 3,3',5-tmodothyronine is concentrated in and delivered from the locus coeruleus to its noradrenergic targets via anterograde axonal transport. Neuroscience 1999;93:943-64.
  • Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry 1993;54:47-54.
  • Joffe RT. Peripheral thyroid hormone levels in treatment resistant depression. Biol Psychiatry 1999;45:1053-5.
  • Fava M, Labbate LA, Abraham ME, Rosenbaum JF. Hypothyroidism and hyperthyroidism in major depression revisited. J Clin Psychiatry 1995;56:186-92.
  • Iosifescu DV, Howarth S, Alpert JE, Nierenberg AA, Worthington JJ, Fava M. T3 blood levels and treatment outcome in depression. Int J Psychiatry Med 2001;31: 367-73.
  • Joffe RT, Roy-Byrne PP, Udhe TW, Post RM. Thyroid function and affective illness: a reappraisal. Biol Psychiatry 1984;19:1685-91.
  • Sandrni M, Vitale G, Vergoni AV, Ottani A, BertoIini A. Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain. Life Sci 1996;58:1551-9.
  • Gur E, Lerer B, Newman ME. Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther 1999;88:81-7.
  • Cleare AJ, McGregor A, O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central S-HT activity and depression. Clin Endocrinol (Oxf) 1995;43:713-9.
  • Cleare AJ, McGregor A, Chambers SM, Dawling S, O'Keane V. Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology 1996;64:65-9.
  • Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001;62(suppl 15):12-7.
  • Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;166:675-82.
  • Marangell LB, Ketter TA, George MS, Pazzaglia PJ, Callahan AM, Parekh P, et al. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Am J Psychiatry 1997;154:224-30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.